What Candel Therapeutics does

Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to treat solid tumors through localized intratumoral injection combined with systemic immune activation. The company's lead asset, aglatimagene besadenovec (CAN-2409), is an adenoviral replication-defective gene construct encoding the herpes simplex virus thymidine kinase gene, which is injected directly into the tumor and, in combination with FDA-approved oral prodrugs such as valacyclovir, triggers immunogenic cell death and CD8+ T cell-mediated anti-tumor immunity. Its second clinical-stage asset, linoserpaturev (CAN-3110), is a replication-competent HSV engineered for tumor-selective replication by placing the ICP34.5 gene under the Nestin promoter, enabling killing of high-grade glioma cells while sparing healthy brain tissue. Both candidates are supported by the enLIGHTEN™ Discovery Platform, an AI-assisted platform for designing new HSV-based gene constructs.

Candel's lead clinical program targets men with intermediate-to high-risk localized prostate cancer; a 745-patient Phase 3 trial under a Special Protocol Assessment met its primary endpoint with a 30% improvement in disease-free survival and an 80% pathological complete response rate, supporting a planned BLA submission in Q4 2026 and a potential U.S. commercial launch in 2027. The company has also reported positive Phase 2 data in non-small cell lung cancer (median OS 25.4 months in ICI-refractory patients), borderline resectable pancreatic cancer (median OS 31.4 months vs 12.5 months in control), and recurrent high-grade glioma, with the NSCLC program funded for Phase 3 development and the pancreatic program paused pending additional capital. Across indications the therapies have received FDA Fast Track, RMAT, and Orphan Drug designations.

The business model is presently pre-revenue. Candel is publicly listed on Nasdaq (ticker: CADL) following a 2021 IPO and operates with a lean headcount of 11-50 employees based in Needham, MA. The company has accumulated roughly $194.8M in cash and equivalents and has secured approximately $230M in additional capital during 2025-2026, including a $130M term loan facility with Trinity Capital, a $100M contingent royalty agreement with RTW Investments, and a $100M public offering, with the stated objective of funding Phase 3 development, launch readiness, and a U.S. commercial launch via an integrated commercialization partnership with EVERSANA. Future revenue, once approved, is expected to derive from product sales of aglatimagene in localized prostate cancer, subject to tiered single-digit royalties owed to RTW on U.S. net sales.

Name

Candel Therapeutics

Legal name

Candel Therapeutics

Website

https://candeltx.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies (adenoviral CAN-2409 and HSV-based CAN-3110) that convert solid tumors into immune-active tissue. It serves patients with prostate, lung, pancreatic, and brain cancers and is preparing a Q4 2026 BLA filing for a 2027 U.S. launch in localized prostate cancer.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Viral immunotherapy
• Cancer immunotherapy
• Oncolytic virus therapy
• Gene therapy oncology
• Solid tumor treatment

Headquarters

HQ city

Needham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Cancer immunotherapy products: Candel Therapeutics is a clinical-stage biopharmaceutical company developing viral immunotherapies for cancer. The company is pre-revenue and not yet commercializing products. It plans to commercialize aglatimagene besadenovec upon FDA approval for localized prostate cancer, with potential commercial launch in 2027. The company has secured non-dilutive royalty funding from RTW Investments contingent on FDA approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Candel Therapeutics develops off-the-shelf, engineered viral immunotherapies for solid tumors, with two clinical-stage investigational products: aglatimagene besadenovec (CAN-2409), an adenoviral gene construct encoding HSV-thymidine kinase injected directly into tumors alongside oral prodrugs to trigger CD8+ T cell-mediated anti-tumor immunity, and linoserpaturev (CAN-3110), a replication-competent HSV engineered for tumor-selective killing in high-grade glioma. The company is preparing for its first commercial launch of aglatimagene in localized prostate cancer, with planned BLA submission in Q4 2026.

Product overview

Candel Therapeutics is a clinical-stage biopharmaceutical company developing two off-the-shelf viral immunotherapy platforms: the adenovirus-based platform producing aglatimagene besadenovec (CAN-2409) and the HSV-based platform producing linoserpaturev (CAN-3110). These are supported by the enLIGHTEN™ Discovery Platform for identifying new therapeutic candidates. The therapies work through localized injection to trigger systemic anti-tumor immune responses.

Differentiator

Problem solved

Functional benefit

Products and services

• Aglatimagene besadenovec (CAN-2409) Adenoviral replication-defective gene construct encoding the HSV-thymidine kinase gene, injected directly into the tumor and combined with oral anti-herpes prodrugs (valacyclovir) to trigger immunogenic cell death and CD8+ T cell-mediated anti-tumor immunity. In development for intermediate-to-high-risk localized prostate cancer (lead indication), NSCLC, and borderline resectable pancreatic cancer.
• Linoserpaturev (CAN-3110) Replication-competent herpes simplex virus engineered for selective killing of cancer cells; the ICP34.5 gene is placed under the Nestin promoter, enabling tumor-selective replication in Nestin-expressing high-grade glioma cells while sparing healthy adult brain cells. Supports multiple dosing without dose-limiting toxicity.

Quantifiable outcome

• 30% improvement in disease-free survival (HR 0.70, p=0.016) in localized prostate cancer Phase 3 trial
• +7 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• EVERSANAcoreChannel Partner/ Reseller/ Distributor · 29 April 2026Candel Therapeutics entered into a product commercialization agreement with EVERSANA to support the potential U.S. commercial launch of aglatimagene besadenovec for intermediate-to high-risk localized prostate cancer. Under the agreement, EVERSANA provides integrated commercialization services including data and analytics, medical affairs, market access, and field operations. The partnership gives Candel access to commercial capabilities while maintaining capital efficiency.
• IDEA PharmasupportingStrategic or Co-development PartnerCandel Therapeutics partnered with IDEA Pharma for strategic positioning as part of pre-commercial workstreams ahead of the potential launch of aglatimagene besadenovec.
• Bali Pulendran, Ph.D.supportingOthersCandel Therapeutics appointed Bali Pulendran, Ph.D., an expert in systems immunology and vaccinology at Stanford University, to its Research Advisory Board. Dr. Pulendran serves as Violetta L. Horton Professor at Stanford University School of Medicine and Director of the Institute for Immunity, Transplantation and Infection.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Adaptimmune Therapeutics: Adaptimmune develops engineered T-cell receptor (TCR) therapies for solid tumors, addressing the same patient populations (sarcoma, NSCLC) and representing a comparable next-generation immuno-oncology modality to Candel's viral immunotherapy.
• Iovance Biotherapeutics: Iovance is an established commercial-stage cell therapy company with FDA-approved tumor-infiltrating lymphocyte therapies for solid tumors, representing a broader oncology immunotherapy peer against which Candel's viral immunotherapy positioning competes for share of voice and capital.
• Ferring Pharmaceuticals / Philogen: Philogen develops targeted immunocytokines and antibody-based therapeutics for solid tumors including prostate cancer, representing an established intratumoral/regional immunotherapy modality competing in the same patient population as Candel.

Direct peers

• Vyriad: Vyriad develops engineered oncolytic vesicular stomatitis and measles virus platforms for solid tumor immunotherapy, with a similar in-situ vaccination mechanism to Candel's viral immunotherapies.
• Genelux Corporation: Genelux is a clinical-stage biopharmaceutical company developing oncolytic vaccinia virus-based therapies for cancer, directly comparable to Candel's engineered virus immunotherapy platform for solid tumors.
• Replimune Group: Replimune is a clinical-stage biotech developing oncolytic immunotherapies based on an engineered herpes simplex virus platform (RP1, RP2, RP3), making it the closest direct competitor to Candel's HSV-based CAN-3110 program and adenoviral CAN-2409 strategy.
• DNAtrix: DNAtrix develops oncolytic adenovirus and HSV therapies for brain tumors, including glioblastoma—the same indication as Candel's CAN-3110. Comparable modality and patient population.
• Oncorus: Oncorus is developing intratumorally and systemically administered oncolytic virus immunotherapies for solid tumors using synthetic virotherapy platforms, comparable to Candel's intratumoral viral immunotherapy approach.
• Istari Oncology: Istari Oncology develops lerapolturev, an oncolytic HSV for recurrent glioblastoma—the same indication as Candel's CAN-3110. Its prior CMO (Garrett Nichols) is now Candel's CMO, signaling deep technical and competitive overlap.

Emerging players

• Turnstone Biologics: Turnstone Biologics is developing viral immunotherapies and tumor-infiltrating lymphocyte therapies for solid tumors, with a comparable intratumoral immunotherapy approach and overlapping solid tumor indications.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/candel-therapeutics
• Xx.com/CandelTx
• Facebookfacebook.com/CandelTx

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds12 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Candel Therapeutics